US 2010/0075891 A1 · Novel polynucleotides encoding polypeptides and methods using same

Novel polynucleotides encoding polypeptides and methods using same

AssigneeCompugen Ltd.

InventorsMichal Ayalon-Soffer, Zurit Levine, Osnat Sella-Tavor, Alex Diber, Ronen Shemesh, Amir Toporik, Galit Rotman, Sergey Nemzer, Avi Rosenberg, Dvir Dahary, Assaf Wool, Gad S. Cojocaru, Pinchas Akiva, Sarah Pollock, Kinneret Savitsky, Jeanne Bernstein

Life of this patent

Estimating the term…

Abstract

Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.

Claims64

Dependent claims

An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70% identical to SEQ ID NO:

1, as determined using the LALIGN software of EMBnet switzerland (www.ch.embnet.org/index.html) using default parameters.

An isolated polypeptide comprising the polypeptide sequence set forth in a member selected from the group consisting of SEQ ID NOs:

1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 54-62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 117, 118, 120, 122, 124, 126, 128-137, 139-155, 157, 158, 160, 161, 162, 164, 165, 166, 168, 169, 171, 172, 173, 175, 176, 178, 179, 182, 184, 186, 187, 189, 190, 192, 193, 195, 196, 198, 199, 200, 202, 203, 204, 258-268, 270, 272, 274, 276, 278, 280, 282, 284, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 326-331, 334, 335, 337, 338, 340, 366, 367, 368, 369, 423-427, 495, 496, 530-537, 555, 556, 557, 564, 565, 631-656, 658-674, 696-699, 702, 727-730, 765-769, 816-821, 849-855, 857-862, 898, 899, 900, 927-933, 956-959, 972, 973, 974, 1000-1012, 1043-1048, 1102-1104, 1127-1131, 1144-1148, 1150, 1152, 1154, and 1155.

A pharmaceutical composition,

comprising an active ingredient comprising a polynucleotide having the polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto, an expression vector comprising a polynucleotide having the polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto, a host cell comprising an expression vector comprising a polynucleotide having a polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto, and a polypeptide comprising the polypeptide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 54-62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 117, 118, 120, 122, 124, 126, 128-137, 139-155, 157, 158, 160, 161, 162, 164, 165, 166, 168, 169, 171, 172, 173, 175, 176, 178, 179, 182, 184, 186, 187, 189, 190, 192, 193, 195, 196, 198, 199, 200, 202, 203, 204, 258-268, 270, 272, 274, 276, 278, 280, 282, 284, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 326-331, 334, 335, 337, 338, 340, 366, 367, 368, 369, 423-427, 495, 496, 530-537, 555, 556, 557, 564, 565, 631-656, 658-674, 696-699, 702, 727-730, 765-769, 816-821, 849-855, 857-862, 898, 899, 900, 927-933, 956-959, 972, 973, 974, 1000-1012, 1043-1048, 1102-1104, 1127-1131, 1144-1148, 1150, 1152, 1154, and 1155, further comprising a pharmaceutically acceptable diluent, excipient or carrier.

2 more elements

A method for detecting a disease related to unwanted expression of an isolated polynucleotide comprising the polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:

3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955;
960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto, comprising detecting overexpression of the polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto in a sample from a patient.

A method for detecting a disease related to unwanted expression of an isolated polypeptide comprising the polypeptide sequence set forth in a member selected from the group consisting of SEQ ID NOs:

1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 54-62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 117, 118, 120, 122, 124, 126, 128-137, 139-155, 157, 158, 160, 161, 162, 164, 165, 166, 168, 169, 171, 172, 173, 175, 176, 178, 179, 182, 184, 186, 187, 189, 190, 192, 193, 195, 196, 198, 199, 200, 202, 203, 204, 258-268, 270, 272, 274, 276, 278, 280, 282, 284, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 326-331, 334, 335, 337, 338, 340, 366, 367, 368, 369, 423-427, 495, 496, 530-537, 555, 556, 557, 564, 565, 631-656, 658-674, 696-699, 702, 727-730, 765-769, 816-821, 849-855, 857-862, 898, 899, 900, 927-933, 956-959, 972, 973, 974, 1000-1012, 1043-1048, 1102-1104, 1127-1131, 1144-1148, 1150, 1152, 1154, and 1155, comprising detecting overexpression of the polypeptide comprising the polypeptide sequence set forth in a member selected from the group consisting of SEQ ID NOs:
1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 54-62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 117, 118, 120, 122, 124, 126, 128-137, 139-155, 157, 158, 160, 161, 162, 164, 165, 166, 168, 169, 171, 172, 173, 175, 176, 178, 179, 182, 184, 186, 187, 189, 190, 192, 193, 195, 196, 198, 199, 200, 202, 203, 204, 258-268, 270, 272, 274, 276, 278, 280, 282, 284, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 326-331, 334, 335, 337, 338, 340, 366, 367, 368, 369, 423-427, 495, 496, 530-537, 555, 556, 557, 564, 565, 631-656, 658-674, 696-699, 702, 727-730, 765-769, 816-821, 849-855, 857-862, 898, 899, 900, 927-933, 956-959, 972, 973, 974, 1000-1012, 1043-1048, 1102-1104, 1127-1131, 1144-1148, 1150, 1152, 1154, and 1155 in a sample from a patient.

A biomarker for detecting a disease related to unwanted expression of an isolated polynucleotide comprising the polynucleotide sequence set forth in a member selected from the group consisting of SEQ ID NOs:

3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto, comprising a nucleotide acid sequence set forth in a member selected from the group consisting of SEQ ID NOs:
3, 4, 7, 8, 11, 12, 15, 16, 19-53, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 116, 119, 121, 123, 125, 127, 138, 156, 159, 163, 167, 170, 174, 177, 180, 181, 183, 185, 188, 191, 194, 197, 201, 205-257, 269, 271, 273, 275, 277, 279, 281, 283, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 325, 332, 333, 336, 339, 341-365, 370-422, 428-494, 497-529, 538-554, 558-563, 566, -630, 657, 675-695, 700, 701, 703-726, 731-764, 770-815, 822-848, 856, 863-897, 901-926, 934-955, 960-971, 975-999, 1013-1042, 1049-1101, 1105-1126, 1132-1143, 1149, 1151 and 1153, or a sequence at least about 95% identical thereto.

Dependencies are inferred from the claim text.